Myriad Genetics

Belkins
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

news image

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More

CELL AND GENE THERAPY

BROOKLYN IMMUNOTHERAPEUTICS ADDED TO ICE BIOTECHNOLOGY INDEX

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

news image

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to...

Read More

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

news image

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More

CONNECTICUT BIOTECH LAUNCHES NEW 3D PRINTED MASK FRAME

Connecticut Biotech | August 14, 2020

news image

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....

Read More
news image

CELL AND GENE THERAPY

BICYCLE THERAPEUTICS ANNOUNCES CONTINUED CLINICAL PROGRESS AND UPDATES TO MANAGEMENT TEAM

Bicycle Therapeutics | January 06, 2022

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary anti-tumor activity in tw...

Read More
news image

CELL AND GENE THERAPY

BROOKLYN IMMUNOTHERAPEUTICS ADDED TO ICE BIOTECHNOLOGY INDEX

Brooklyn ImmunoTherapeutics, Inc. | December 18, 2021

Brooklyn ImmunoTherapeutics, Inc. on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announces that Brooklyn has been added to the ICE Biotechnology Index following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposition and approach to...

Read More
news image

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More
news image

CONNECTICUT BIOTECH LAUNCHES NEW 3D PRINTED MASK FRAME

Connecticut Biotech | August 14, 2020

Connecticut Biotech, a new innovative start-up company, is announcing the launch of its Secure Fit 3D-printed face mask frame. The mask frames are an exoskeleton worn outside of a traditional surgical mask, providing enhanced efficacy in protection against COVID-19 and other airborne pathogens. Secure Fit is a reusable, reliable device designed to make day-to-day interactions safer for users.In partnership with the University of Connecticut and under the leadership of surgeon-scientist Dr....

Read More